Exogenous nitric oxide causes overexpression of TGF-β1 and overproduction of extracellular matrix in human coronary smooth muscle cells

Cardiovascular Research

Volumn 58, Issue 3, 2003, Pages 671-678

  Schmidt, Annette ^a   Geigenmueller, Sven ^a   Voelker, Wolfgang ^a   Seiler, Petra ^a   Buddecke, Eckhart ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Connective tissue; Gene expression; Growth factor; Nitric oxide; Smooth muscle

Indexed keywords

1 [(2 AMINOETHYL) N (2 AMINOETHYL)AMINO]DIAZEN 1 IUM 1,2 DIOLATE; CHONDROITIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DERMATAN SULFATE; HEPARAN SULFATE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE DONOR; PROLINE; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA1; TRITIUM; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BIOACCUMULATION; CARDIOVASCULAR SYSTEM; CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; EXTRACELLULAR MATRIX; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; ISOTOPE LABELING; MOLECULAR STABILITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RNA TRANSCRIPTION; RNA TRANSLATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

CELLS, CULTURED; CORONARY VESSELS; DEET; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMANS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE DONORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STIMULATION, CHEMICAL; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 0037531380     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(03)00322-5     Document Type: Article

References (30)

1. Lloyd-Jones I.M., Block K.D. The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med. 47:1996;365-375.
2. Mallis R.J., Buss J.E., Thomas J.A. Oxidative modification of H-ras: S-thiolation and S-nitrosylation of reactive cysteines. Biochem J. 355:2001;145-153.
3. Castel H., Vaudry H. Nitric oxide directly activates GABA(A) receptor function through a cGMP/protein kinase-independent pathway in frog pituitary melanotrophs. J Neuroendocrinol. 13:2001;695-705.
4. Sun J., Xin C., Eu J.P., Stamler J.S., Meissner G. Cysteine-3635 is responsible for skeletal muscle ryanodine receptor modulation by NO. Proc Natl Acad Sci USA. 98:2001;11158-11162.
5. Clancy R.M., Leszczynska P., Piziak J., Abramson S.B. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on NADPH oxidase. J Clin Invest. 90:1992;1116-1121.
6. Kosonen O., Kankaanranta H., Uotila J., Moilanen E. Inhibition by nitric oxide-releasing compounds of E-selectin expression in and neutrophil adhesion to human endothelial cells. Eur J Pharmacol. 394:2000;149-156.
7. Villarreal D., Grisham M.B., Granger D.N. Nitric oxide donors improve gut function after prolonged hypothermic ischemia. Transplantation. 59:1995;685-689.
8. Mellion B.T., Ignarro L.J., Ohlstein E.H., et al. Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP induced human platelet aggregation in the presence of nitric oxide and related vasodilator. Blood. 57:1981;946-955.
9. Mooradian D.L., Hutsell T.C., Keefer L.K. Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro. J Cardiovasc Pharmacol. 25:1995;674-678.
10. Young D.V., Serebryanik D., Janero D.R., Tam S.W. Suppression of proliferation of human coronary artery smooth muscle cells by the nitric oxide donor, S-nitrosoglutathione, is cGMP-independent. Mol Cell Biol Res Commun. 4:2000;32-36.
11. Sarkar R., Gordon D., Stanley J.C., Webb R.C. Cell cycle effects of nitric oxide on vascular smooth muscle cells. Am J Physiol. 272:1997;1810-1818.
12. Garg U.C., Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 83:1989;1774-1777.
13. Coke J.P., Tsao P.S. Arginine: a new therapy for atherosclerosis. Circulation. 1997;311-312.
14. Hrabie J.A., Klose J.R., Wink D.A., Keefer L.K. New nitric oxide-releasing zwitterions derived from polyamines. J Org Chem. 58:1993;1472-1476.
15. Schmidt A., Vlodavsky I., Völker W., Buddecke E. Induction of a hypertrophic growth status of coronary smooth muscle cells is associated with an overexpression of TGF-β Eur J Cell Biol. 81:2002;138-144.
16. Schmidt A., Vlodavsky I., Völker W., Buddecke E. Differentiation of coronary smooth muscle cells to a cell cycle-arrested hypertrophic growth status by a synthetic non-toxic heparin-mimicking compound. Atherosclerosis. 147:1999;387-397.
17. Keefer L.K., Nims R.W., Davies K.M., Wink D.A. 'NONOates' (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol. 268:1996;281-293.
18. Schulz R., Schmidt D., Blum A., et al. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax. 55:2000;1046-1051.
19. Vogt D., Trenk D., Bonn R., Jähnchen E. Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. Eur J Clin Pharmacol. 46:1994;319-324.
20. McCaffrey T.A. TGF-betas and TGF-beta receptors in atherosclerosis. Cytokine Growth Factor Rev. 11:2000;103-114.
21. Wight T.N. Cell biology of arterial proteoglycans. Arteriosclerosis. 9:1989;1-20.
22. Amento E.P., Ehsani N., Palmer H., Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb. 11:1991;1223-1230.
23. 1 stimulates type V collagen expression in bovine vascular smooth muscle cells. J Biol Chem. 269:1994;9603-9609.
24. 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler Thromb. 13:1993;1026-1036.
25. Evanko S.P., Raines E.W., Ross R., Gold L.I., Wight T.N. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am J Pathol. 152:1998;533-546.
26. Little P.J., Tannock L., Olin K.L., Chait A., Wight T.N. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler Thromb Vasc Biol. 22:2002;55-60.
27. 1 inhibits proteoglycan synthesis in arterial wall. J Vasc Res. 31:1994;322-329.
28. Grainger D.J., Kemp P.R., Metcalfe J.C., et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med. 1:1995;74-79.
29. Aiba M., Takeyoshi I., Ohwada S., et al. Novel nitric oxide donor (FK409) ameliorates liver damage during extended liver resection with warm ischemia in dogs. J Am Coll Surg. 193:2001;264-271.
30. Hirasawa Y., Nishio M., Maeda K., Yoshida K., Kita Y. Comparison of antiplatelet effects of FK409, a spontaneous nitric oxide releaser, with those of TRK-100, a prostacyclin analogue. Eur J Pharmacol. 272:1995;39-43.